Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

360
Delayed Quote. Delayed Euronext Alternext - 01/23 11:24:20 am
1.16 EUR   -1.69%
01/22 NEOVACS : to present at BIO CEO Investor Conference
01/19 NEOVACS : To present at bio ceo & investor conference
01/14 NEOVACS : Half-year report on the liquidity contract
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
01/19/2015 01/20/2015 01/21/2015 01/22/2015 01/23/2015 Date
1.15(c) 1.17(c) 1.17(c) 1.18(c) 1.16(c) Last
139 773 184 456 180 458 71 189 115 614 Volume
-0.86% +1.74% 0.00% +0.85% -1.69% Change
More quotes
Company
Neovacs SA is a biotechnology company.It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer.It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid.The Tumor Necrosis... 
Sector
Biotechnology & Medical Research
Calendar
02/09 | 09:30amPresentation
More about the company
Surperformance© ratings of NEOVACS
Trading Rating : Investor Rating :
More Ratings
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 0,03 M
EBIT 2014 -7,94 M
Net income 2014 -6,86 M
Debt 2014 3,05 M
Yield 2014 -
Sales 2015 10,0 M
EBIT 2015 -3,40 M
Net income 2015 -6,70 M
Debt 2015 8,28 M
Yield 2015 -
PER 2014 -
PER 2015 0,33
EV / Sales 2014 991x
EV / Sales 2015 3,50x
Capitalization 26,7 M
More Financials
Latest news on NEOVACS
01/22 NEOVACS : to present at BIO CEO Investor Conference
01/19 NEOVACS : To present at bio ceo & investor conference
01/19 NEOVACS : TO PRESENT AT BIO CEO & INVESTOR CONFERENCE (DGAP News)
01/14 NEOVACS : Half-year report on the liquidity contract
2014 NEOVACS : Announces top line phase iib clinical trial results of tnf-kinoid in r..
2014 NEOVACS : ANNOUNCES TOP LINE PHASE IIB CLINICAL TRIAL RESULTS OF TNF-KINOID IN R..
2014 NEOVACS : granted 1 million euro in Research Tax Credit
2014 NEOVACS : Granted 1 million euro in research tax credit
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF